Sagimet Announces Positive 52-Week Phase 3 OLE Results for Denifanstat, Preps U.S. Phase 3 Start
Sagimet announced positive 52-week open-label extension results for denifanstat showing sustained efficacy and tolerability.Key Highlights:Original SEC Filing: Sagimet Biosciences Inc. [ SGMT ] - 8-K - Sep. 30, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying impor…